Loading...

Webster Cavenee

TitleEmeritus Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0660
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee W, Furnari FB. Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2018 May 25; 9:16217. PMID: 29799523.
      View in: PubMed
    2. Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee W, Das SK, Emdad L, Fisher PB. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proc Natl Acad Sci U S A. 2018 May 14. PMID: 29760085.
      View in: PubMed
    3. Benitez JA, Zanca C, Ma J, Cavenee W, Furnari FB. Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. J Vis Exp. 2018 04 26; (134). PMID: 29757276.
      View in: PubMed
    4. Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M. FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene. 2018 Mar; 37(10):1386-1398. PMID: 29321665.
      View in: PubMed
    5. Newman JP, Wang GY, Arima K, Guan SP, Waters MR, Cavenee W, Pan E, Aliwarga E, Chong ST, Kok CYL, Endaya BB, Habib AA, Horibe T, Ng WH, Ho IAW, Hui KM, Kordula T, Lam PYP. Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nat Commun. 2017 Dec 04; 8(1):1913. PMID: 29203859.
      View in: PubMed
    6. Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee W, Pasqualini R, Arap W. Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses. EMBO Mol Med. 2017 Oct; 9(10):1327-1330. PMID: 28751581.
      View in: PubMed
    7. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee W, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 Feb 15; 24(4):737-743. PMID: 28814435.
      View in: PubMed
    8. Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee W, Furnari FB. Glioblastoma cellular cross-talk converges on NF-?B to attenuate EGFR inhibitor sensitivity. Genes Dev. 2017 Jul 19. PMID: 28724615.
      View in: PubMed
    9. Cai J, Lin Y, Zhang H, Liang J, Tan Y, Cavenee W, Yan G. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci U S A. 2017 06 27; 114(26):6812-6817. PMID: 28607091.
      View in: PubMed
    10. Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee W, Furnari FB. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2017 May 12; 8:15223. PMID: 28497778.
      View in: PubMed
    11. Liu F, Mischel PS, Cavenee W. Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. NPJ Precis Oncol. 2017; 1(1):1. PMID: 29872691.
      View in: PubMed
    12. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee W, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017 03 02; 543(7643):122-125. PMID: 28178237.
      View in: PubMed
    13. Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee W, Wei J, Purves A, De SK, Pellecchia M, Fisher PB. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proc Natl Acad Sci U S A. 2017 01 10; 114(2):370-375. PMID: 28011764.
      View in: PubMed
    14. Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee W, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, Ljubimov AV, Ljubimova JY. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release. 2016 Dec 28; 244(Pt A):14-23. PMID: 27825958.
      View in: PubMed
    15. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee W, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14; 30(5):683-693. PMID: 27746144.
      View in: PubMed
    16. Masui K, Shibata N, Cavenee W, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays. 2016 09; 38(9):839-44. PMID: 27427440.
      View in: PubMed
    17. Masui K, Cavenee W, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathol. 2016 Jul; 33(3):161-8. PMID: 27295313.
      View in: PubMed
    18. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun; 131(6):803-20. PMID: 27157931.
      View in: PubMed
    19. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee W, Cloughesy TF, Mischel PS, Heath JR, Gini B. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 2016 Apr 11; 29(4):563-573. PMID: 27070703.
      View in: PubMed
    20. Masui K, Cavenee W, Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathol. 2015 Nov; 25(6):755-9. PMID: 26526943; PMCID: PMC4636016 [Available on 11/01/16].
    21. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee W, Ren B, Mischel PS. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell. 2015 Oct 15; 60(2):307-18. PMID: 26455392; PMCID: PMC4609298 [Available on 10/15/16].
    22. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee W, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A. 2015 Jul 28; 112(30):9406-11. PMID: 26170313; PMCID: PMC4522814.
    23. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee W, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8. PMID: 26080435; PMCID: PMC4500257.
    24. Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, Furnari FB, Cavenee W, Desai A, Chen CC. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget. 2015 May 20; 6(14):11751-67. PMID: 26059434.
      View in: PubMed
    25. Furnari FB, Cloughesy TF, Cavenee W, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015 May; 15(5):302-10. PMID: 25855404; PMCID: PMC4875778.
    26. Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee W, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A. 2015 Jan 27; 112(4):1107-12. PMID: 25583476; PMCID: PMC4313862.
    27. Wu SH, Bi JF, Cloughesy T, Cavenee W, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014 Dec; 11(4):255-63. PMID: 25610711; PMCID: PMC4296088.
    28. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee W, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 2015 Jan 15; 75(2):394-404. PMID: 25432173; PMCID: PMC4297573.
    29. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee W, Hu B, Yan H, Cheng SY. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest. 2014 Sep; 124(9):3741-56. PMID: 25061874; PMCID: PMC4151226.
    30. Masui K, Cavenee W, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab. 2014 Jul; 25(7):364-73. PMID: 24856037; PMCID: PMC4077930.
    31. Costa ET, Barnabé GF, Li M, Dias AA, Machado TR, Asprino PF, Cavalher FP, Ferreira EN, Del Mar Inda M, Nagai MH, Malnic B, Duarte ML, Leite KR, de Barros AC, Carraro DM, Chammas R, Armelin HA, Cavenee W, Furnari F, Camargo AA. Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. Oncogene. 2015 Mar 05; 34(10):1270-9. PMID: 24662834.
      View in: PubMed
    32. Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, Chen CC. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 2014 Feb 28; 5(4):882-93. PMID: 24658464; PMCID: PMC4011590.
    33. Masui K, Cavenee W, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle. 2014; 13(7):1053-4. PMID: 24583874; PMCID: PMC4013152.
    34. Kawashima N, Qu H, Lobaton M, Zhu Z, Sollogoub M, Cavenee W, Handa K, Hakomori SI, Zhang Y. Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation. Oncol Lett. 2014 Apr; 7(4):933-940. PMID: 24944646.
      View in: PubMed
    35. Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee W. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res. 2014 Mar 01; 74(5):1429-39. PMID: 24436148; PMCID: PMC3947420.
    36. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee W, Furnari FB, Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 03; 343(6166):72-6. PMID: 24310612; PMCID: PMC4049335.
    37. Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee W. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med. 2013 Dec; 10(4):192-205. PMID: 24349829; PMCID: PMC3860350.
    38. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee W, Shaw RJ, Mischel PS. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013 Nov 05; 18(5):726-39. PMID: 24140020; PMCID: PMC3840163.
    39. Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee W, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15; 19(20):5722-32. PMID: 24030701; PMCID: PMC3815450.
    40. Cloughesy TF, Cavenee W, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014; 9:1-25. PMID: 23937436.
      View in: PubMed
    41. Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee W, Cloughesy TF, Christofk HR, Black DL, Mischel PS. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013 Jun 04; 17(6):1000-8. PMID: 23707073; PMCID: PMC3679227.
    42. Iwanami A, Cloughesy TF, Cavenee W, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle. 2013 May 15; 12(10):1473-4. PMID: 23624839; PMCID: PMC3680520.
    43. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee W, Bensinger SJ, Mischel PS. De-repression of PDGFRß transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013 May; 3(5):534-47. PMID: 23533263; PMCID: PMC3651754.
    44. Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee W. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 2013 Apr; 34(4):725-38. PMID: 23455378; PMCID: PMC3616676.
    45. Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee W, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel PS. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4339-44. PMID: 23440206; PMCID: PMC3600508.
    46. Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee W, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. PLoS Genet. 2013; 9(2):e1003253. PMID: 23459592; PMCID: PMC3573097.
    47. Cavenee W. Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1073-4. PMID: 22911109.
      View in: PubMed
    48. Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee W, Furnari FB. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14164-9. PMID: 22891331; PMCID: PMC3435194.
    49. Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee W, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer. 2013 Feb 01; 132(3):509-20. PMID: 22729867; PMCID: PMC3802533.
    50. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee W, Depinho RA, Chin L, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84. PMID: 22508724; PMCID: PMC3337451.
    51. Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee W, Cheng SY. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3018-23. PMID: 22323579; PMCID: PMC3286964.
    52. Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med. 2011 Dec 19; 208(13):2657-73. PMID: 22162832; PMCID: PMC3244036.
    53. Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, Nishikawa R, Cavenee W, Cheng SY. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRa-stimulated glioma tumorigenesis in mice and humans. J Clin Invest. 2011 Dec; 121(12):4670-84. PMID: 22080864; PMCID: PMC3223070.
    54. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee W, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. Oncogenic EGFR signaling activates an mTORC2-NF-?B pathway that promotes chemotherapy resistance. Cancer Discov. 2011 Nov; 1(6):524-38. PMID: 22145100; PMCID: PMC3229221.
    55. Hu J, Jo M, Cavenee W, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A. 2011 Sep 20; 108(38):15984-9. PMID: 21896743; PMCID: PMC3179096.
    56. Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee W, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci. 2011 Sep 01; 124(Pt 17):2938-50. PMID: 21878501; PMCID: PMC3706030.
    57. Wang Y, Huang JW, Li M, Cavenee W, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res. 2011 Aug; 9(8):1100-11. PMID: 21693595; PMCID: PMC3157593.
    58. Bonavia R, Inda MM, Cavenee W, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011 Jun 15; 71(12):4055-60. PMID: 21628493; PMCID: PMC3117065.
    59. Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee W, Furnari FB, Bogler O. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ?EGFR. J Proteome Res. 2011 Mar 04; 10(3):1343-52. PMID: 21214269; PMCID: PMC3049961.
    60. Wykosky J, Fenton T, Furnari F, Cavenee W. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer. 2011 Jan; 30(1):5-12. PMID: 21192840; PMCID: PMC3359794.
    61. Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Höök M, Gelovani JG, Sidman RL, Cavenee W, Pasqualini R, Arap W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest. 2011 Jan; 121(1):161-73. PMID: 21183793; PMCID: PMC3007161.
    62. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010 Aug 15; 24(16):1731-45. PMID: 20713517; PMCID: PMC2922502.
    63. Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee W, Robertson GP. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst. 2010 Aug 04; 102(15):1131-47. PMID: 20660366; PMCID: PMC2914760.
    64. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee W, D'Andrea A, Chen CC. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One. 2010 May 24; 5(5):e10767. PMID: 20532243; PMCID: PMC2879424.
    65. Wykosky J, Mukasa A, Furnari F, Cavenee W. Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle. 2010 May; 9(9):1661-2. PMID: 20404502.
      View in: PubMed
    66. Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, Cavenee W, Furnari FB, White FM. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol Biosyst. 2010 Jul; 6(7):1227-37. PMID: 20461251; PMCID: PMC3291333.
    67. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee W, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A. 2010 Feb 09; 107(6):2616-21. PMID: 20133782; PMCID: PMC2823874.
    68. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee W, Johns TG, Mischel PS. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 01; 69(17):6889-98. PMID: 19690143; PMCID: PMC2770839.
    69. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee W, Bachoo RM, Burma S. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res. 2009 May 15; 69(10):4252-9. PMID: 19435898; PMCID: PMC2694953.
    70. Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee W, Old LJ, Stockert E, Ritter G, Adams TE, Hoyne PA, Wittrup D, Chao G, Cochran JR, Luo C, Lou M, Huyton T, Xu Y, Fairlie WD, Yao S, Scott AM, Johns TG. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A. 2009 Mar 31; 106(13):5082-7. PMID: 19289842; PMCID: PMC2656555.
    71. James CD, Cavenee W. Stem cells for treating glioblastoma: how close to reality? Neuro Oncol. 2009 Apr; 11(2):101. PMID: 19237733; PMCID: PMC2718980.
    72. Read RD, Cavenee W, Furnari FB, Thomas JB. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet. 2009 Feb; 5(2):e1000374. PMID: 19214224; PMCID: PMC2636203.
    73. Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee W, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, Ligon KL, Futreal PA, Chin L. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64. PMID: 18394558; PMCID: PMC2292238.
    74. Roeb W, Boyer A, Cavenee W, Arden KC. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle. 2008 Apr 01; 7(7):837-41. PMID: 18414034.
      View in: PubMed
    75. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee W, Cloughesy TF, Mischel PS. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15; 14(2):488-93. PMID: 18223223.
      View in: PubMed
    76. Barrera LO, Li Z, Smith AD, Arden KC, Cavenee W, Zhang MQ, Green RD, Ren B. Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res. 2008 Jan; 18(1):46-59. PMID: 18042645; PMCID: PMC2134779.
    77. Roeb W, Boyer A, Cavenee W, Arden KC. PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci U S A. 2007 Nov 13; 104(46):18085-90. PMID: 17986608; PMCID: PMC2084300.
    78. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee W. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710. PMID: 17974913.
      View in: PubMed
    79. Huang PH, Cavenee W, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle. 2007 Nov 15; 6(22):2750-4. PMID: 17986864.
      View in: PubMed
    80. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee W, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 2007 Jul 31; 104(31):12867-72. PMID: 17646646; PMCID: PMC1937558.
    81. Louis DN, Ohgaki H, Wiestler OD, Cavenee W, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug; 114(2):97-109. PMID: 17618441; PMCID: PMC1929165.
    82. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee W, Scott AM, Furnari FB. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res. 2007 Mar 15; 13(6):1911-25. PMID: 17363548.
      View in: PubMed
    83. Nagane M, Cavenee W, Shiokawa Y. Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg. 2007 Mar; 106(3):407-16. PMID: 17367063.
      View in: PubMed
    84. Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee W, Old LJ, Demetri GD, Wong KK. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest. 2007 Feb; 117(2):346-52. PMID: 17256054; PMCID: PMC1770949.
    85. Finckenstein FG, Davicioni E, Osborn KG, Cavenee W, Arden KC, Anderson MJ. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Res. 2006 Oct; 15(5):595-614. PMID: 16952014.
      View in: PubMed
    86. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee W, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006 Aug 15; 66(16):7864-9. PMID: 16912159.
      View in: PubMed
    87. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee W, Furnari FB. PCAF modulates PTEN activity. J Biol Chem. 2006 Sep 08; 281(36):26562-8. PMID: 16829519.
      View in: PubMed
    88. Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee W, Furnari FB, Depinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell. 2006 May; 9(5):379-90. PMID: 16697958.
      View in: PubMed
    89. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee W, Chen W, Low WC. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol. 2006 Jan; 76(1):23-30. PMID: 16155724.
      View in: PubMed
    90. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee W, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. PMID: 16282176.
      View in: PubMed
    91. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee W, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res. 2005 Sep 01; 11(17):6390-9. PMID: 16144944.
      View in: PubMed
    92. Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee W. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle. 2005 Apr; 4(4):540-2. PMID: 15753657.
      View in: PubMed
    93. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee W. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A. 2005 Feb 22; 102(8):2703-6. PMID: 15659546; PMCID: PMC549467.
    94. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee W, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005 Jan; 4(1):101-12. PMID: 15657358.
      View in: PubMed
    95. Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee W, Dikic I, Bögler O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Mol Cell Biol. 2004 Oct; 24(20):8981-93. PMID: 15456872; PMCID: PMC517880.
    96. Hosaka T, Biggs WH, Tieu D, Boyer AD, Varki NM, Cavenee W, Arden KC. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2975-80. PMID: 14978268; PMCID: PMC365730.
    97. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee W, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol. 2004; 21(2):53-6. PMID: 15700833.
      View in: PubMed
    98. Cavenee W. The recessive nature of dominance. Genes Chromosomes Cancer. 2003 Dec; 38(4):322-5. PMID: 14566850.
      View in: PubMed
    99. Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, Ojopi EP, Osorio EC, Reis EM, Riggins GJ, Simpson AJ, de Souza S, Stevenson BJ, Strausberg RL, Tajara EH, Verjovski-Almeida S, Acencio ML, Bengtson MH, Bettoni F, Bodmer WF, Briones MR, Camargo LP, Cavenee W, Cerutti JM, Coelho Andrade LE, Costa dos Santos PC, Ramos Costa MC, da Silva IT, Estécio MR, Sa Ferreira K, Furnari FB, Faria M, Galante PA, Guimaraes GS, Holanda AJ, Kimura ET, Leerkes MR, Lu X, Maciel RM, Martins EA, Massirer KB, Melo AS, Mestriner CA, Miracca EC, Miranda LL, Nobrega FG, Oliveira PS, Paquola AC, Pandolfi JR, Campos Pardini MI, Passetti F, Quackenbush J, Schnabel B, Sogayar MC, Souza JE, Valentini SR, Zaiats AC, Amaral EJ, Arnaldi LA, de Araújo AG, de Bessa SA, Bicknell DC, Ribeiro de Camaro ME, Carraro DM, Carrer H, Carvalho AF, Colin C, Costa F, Curcio C, Guerreiro da Silva ID, Pereira da Silva N, Dellamano M, El-Dorry H, Espreafico EM, Scattone Ferreira AJ, Ayres Ferreira C, Fortes MA, Gama AH, Giannella-Neto D, Giannella ML, Giorgi RR, Goldman GH, Goldman MH, Hackel C, Ho PL, Kimura EM, Kowalski LP, Krieger JE, Leite LC, Lopes A, Luna AM, Mackay A, Mari SK, Marques AA, Martins WK, Montagnini A, Mourão Neto M, Nascimento AL, Neville AM, Nobrega MP, O'Hare MJ, Otsuka AY, Ruas de Melo AI, Paco-Larson ML, Guimarães Pereira G, Pereira da Silva N, Pesquero JB, Pessoa JG, Rahal P, Rainho CA, Rodrigues V, Rogatto SR, Romano CM, Romeiro JG, Rossi BM, Rusticci M, Guerra de Sá R, Sant' Anna SC, Sarmazo ML, Silva TC, Soares FA, Sonati Mde F, de Freitas Sousa J, Queiroz D, Valente V, Vettore AL, Villanova FE, Zago MA, Zalcberg H. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A. 2003 Nov 11; 100(23):13418-23. PMID: 14593198; PMCID: PMC263829.
    100. Hu B, Guo P, Fang Q, Tao HQ, Wang D, Nagane M, Huang HJ, Gunji Y, Nishikawa R, Alitalo K, Cavenee W, Cheng SY. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A. 2003 Jul 22; 100(15):8904-9. PMID: 12861074; PMCID: PMC166411.
    101. Li Z, Van Calcar S, Qu C, Cavenee W, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8164-9. PMID: 12808131; PMCID: PMC166200.
    102. Schmidt MH, Furnari FB, Cavenee W, Bögler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A. 2003 May 27; 100(11):6505-10. PMID: 12734385; PMCID: PMC164476.
    103. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee W, Cheng SY. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol. 2003 Apr; 162(4):1083-93. PMID: 12651601; PMCID: PMC1851242.
    104. Cavenee W. Preparing for serendipity. Cancer Biol Ther. 2003 Mar-Apr; 2(2):213-5. PMID: 12750567.
      View in: PubMed
    105. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee W, Old LJ, Cavanee WK. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 2003 Jan 21; 100(2):639-44. PMID: 12515857; PMCID: PMC141049.
    106. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee W. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002 Nov 15; 62(22):6764-9. PMID: 12438278.
      View in: PubMed
    107. Cavenee W. Muscling in on rhabdomyosarcoma. Nat Med. 2002 Nov; 8(11):1200-1. PMID: 12411939.
      View in: PubMed
    108. Nakae J, Biggs WH, Kitamura T, Cavenee W, Wright CV, Arden KC, Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet. 2002 Oct; 32(2):245-53. PMID: 12219087.
      View in: PubMed
    109. Cavenee W. Genetics and new approaches to cancer therapy. Carcinogenesis. 2002 May; 23(5):683-6. PMID: 12016138.
      View in: PubMed
    110. De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee W. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. J Neurochem. 2002 May; 81(3):575-88. PMID: 12065666.
      View in: PubMed
    111. Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee W, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer. 2002 Mar 20; 98(3):398-408. PMID: 11920591.
      View in: PubMed
    112. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee W. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002 Mar; 61(3):215-25; discussion 226-9. PMID: 11895036.
      View in: PubMed
    113. Steinbach JP, Supra P, Huang HJ, Cavenee W, Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol. 2002 Jan; 12(1):12-20. PMID: 11770895.
      View in: PubMed
    114. Costello JF, Plass C, Cavenee W. Restriction landmark genome scanning. Methods Mol Biol. 2002; 200:53-70. PMID: 11951655.
      View in: PubMed
    115. Nagane M, Huang HJ, Cavenee W. Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma. Drug Resist Updat. 1999 Feb; 2(1):30-37. PMID: 11504467.
      View in: PubMed
    116. Besnard-Guérin C, Cavenee W, Newsham I. The t(11;22)(p15.5;q11.23) in a retroperitoneal rhabdoid tumor also includes a regional deletion distal to CRYBB2 on 22q. Genes Chromosomes Cancer. 1995 Jul; 13(3):145-50. PMID: 7669732.
      View in: PubMed
    117. Newsham I, Kindler-Röhrborn A, Daub D, Cavenee W. A constitutional BWS-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in Wilms' tumors. Genes Chromosomes Cancer. 1995 Jan; 12(1):1-7. PMID: 7534105.
      View in: PubMed
    118. Newsham I, Daub D, Besnard-Guerin C, Cavenee W. Molecular sublocalization and characterization of the 11;22 translocation breakpoint in a malignant rhabdoid tumor. Genomics. 1994 Feb; 19(3):433-40. PMID: 8188285.
      View in: PubMed
    119. Winqvist R, Mannermaa A, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee W. Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors. Cancer Res. 1993 Oct 01; 53(19):4486-8. PMID: 8402619.
      View in: PubMed
    120. Gessler M, König A, Moore J, Qualman S, Arden K, Cavenee W, Bruns G. Homozygous inactivation of WT1 in a Wilms' tumor associated with the WAGR syndrome. Genes Chromosomes Cancer. 1993 Jul; 7(3):131-6. PMID: 7687865.
      View in: PubMed
    121. Gerken S, Leppert M, O'Connell P, Cavenee W, James CD, Ballard L, Stauffer D, Elsner T, Plaetke R, Lalouel JM. A genetic linkage map with 29 loci spanning human chromosome 13q. Genomics. 1993 May; 16(2):515-9. PMID: 8100218.
      View in: PubMed
    122. Newsham I, Cavenee W. Tumors and developmental anomalies associated with Wilms tumor. Med Pediatr Oncol. 1993; 21(3):199-204. PMID: 8383280.
      View in: PubMed
    123. Newsham I, Artigas C, Lasko D, Cavenee W. Characterization of polymorphic and monomorphic loci for chromosome 11p15.5. Mamm Genome. 1993; 4(8):451-3. PMID: 8104058.
      View in: PubMed
    124. Newsham I, Claussen U, Lüdecke HJ, Mason M, Senger G, Horsthemke B, Cavenee W. Microdissection of chromosome band 11p15.5: characterization of probes mapping distal to the HBBC locus. Genes Chromosomes Cancer. 1991 Mar; 3(2):108-16. PMID: 1676905.
      View in: PubMed
    125. Phaneuf D, Labelle Y, Bérubé D, Arden K, Cavenee W, Gagné R, Tanguay RM. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet. 1991 Mar; 48(3):525-35. PMID: 1998338; PMCID: PMC1682993.
    126. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990 Feb 22; 343(6260):774-8. PMID: 2154702.
      View in: PubMed
    127. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza C. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A. 1989 Oct; 86(19):7480-4. PMID: 2798419; PMCID: PMC298088.
    128. Scrable H, Witte D, Shimada H, Seemayer T, Sheng WW, Soukup S, Koufos A, Houghton P, Lampkin B, Cavenee W. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer. 1989 Sep; 1(1):23-35. PMID: 2487144.
      View in: PubMed
    129. Finver SN, Martiniere C, Kagan J, Cavenee W, Croce CM. The chromosome 11 region flanking the t(11;14) breakpoint in human T-ALL is deleted in Wilms' tumor hybrids. Oncogene Res. 1989; 5(2):143-8. PMID: 2558334.
      View in: PubMed